title: Secretory leukoprotease inhibitor inhibits cell growth through apoptotic pathway on ovarian cancer.
abstract: In light of the poor prognosis for ovarian cancer, research continues for innovative and efficacious treatment modalities. It is now widely accepted that new approaches for the treatment of ovarian cancers are pivotal in further improving prognosis of this disease. Secretory leukoprotease inhibitor (SLPI) is an 11.7-kDa non-glycosylated, serine protease inhibitor that has a broad inhibitory spectrum against serine protease. SLPI showed potential therapeutic inhibitory effects mediated by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), TNF-alpha, death receptor (DR)-4, DR-5 and TNF receptor (TNFR)-I expression which lead to an activation of apoptosis pathway through Caspase-2, Caspase-8 and Caspase-9. We examined whether levels of SLPI protein expression correlated with clinicopathological characteristics in 58 ovarian cancer samples, and investigated the role of SLPI and its biological functions. SLPI expression showed a significant correlation between low expression of SLPI and amount of ascites (p=0.021), lymph node metastasis (p=0.011). We propose that SLPI could be considered a therapeutic target for the treatment of ovarian cancer.
authors.affiliation: Department of Obstetrics and Gynecology, Okayama University Graduate School of Medical, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan. k-nakamu@cc.okayama-u.ac.jp
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Nakamura
authors.forename: Norio
authors.initials: N
authors.lastname: Takamoto
authors.forename: Atsushi
authors.initials: A
authors.lastname: Hongo
authors.forename: Junichi
authors.initials: J
authors.lastname: Kodama
authors.forename: Fernando
authors.initials: F
authors.lastname: Abrzua
authors.forename: Yasutomo
authors.initials: Y
authors.lastname: Nasu
authors.forename: Hiromi
authors.initials: H
authors.lastname: Kumon
authors.forename: Yuji
authors.initials: Y
authors.lastname: Hiramatsu
mesh_terms: D020169:Caspases / Q000096:biosynthesis; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D005260:Female; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D006031:Glycosylation; D006801:Humans; D010051:Ovarian Neoplasms / Q000201:enzymology* / Q000473:pathology* / Q000628:therapy; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000378:metabolism; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000096:biosynthesis; D053481:Secretory Leukocyte Peptidase Inhibitor / Q000096:biosynthesis*; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D047888:Receptors, Tumor Necrosis Factor, Type I; D053481:Secretory Leukocyte Peptidase Inhibitor; D053221:TNF-Related Apoptosis-Inducing Ligand; D014409:Tumor Necrosis Factor-alpha; D020169:Caspases